Aclaris Therapeutics, Inc. (ACRS) Financial Statements (2026 and earlier)

Company Profile

Business Address 701 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:203,900181,900229,800225,70054,10075,015
Cash and cash equivalent24,57039,87845,27727,34922,063 
Short-term investments89,02479,228172,294164,06532,06839,078
Other undisclosed cash, cash equivalents, and short-term investments90,30662,79412,22934,286(31)35,937
Receivables 318298484623772704
Disposal group, including discontinued operation      4,966
Other undisclosed current assets(78,267)(53,342)1,266(21,291)2,6213,118
Total current assets:125,951128,856231,550205,03257,49383,803
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,0081,6201,0991,3351,6542,470
Long-term investments and receivables90,30262,77112,24234,242  
Long-term investments90,30262,77112,24234,242  
Intangible asset, including goodwill, after accumulated amortization  2696,9737,0487,1237,199
Intangible asset, excluding goodwill, after accumulated amortization  2696,9737,0487,1237,199
Other noncurrent assets3,0663,8892,7323,5544,5144,825
Total noncurrent assets:94,37668,54923,04646,17913,29114,494
TOTAL ASSETS:220,327197,405254,596251,21170,78498,297
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities25,02328,32419,05220,03611,16017,638
Accounts payable4,6908,87810,3519,9855,2549,917
Accrued liabilities20,33319,4468,70110,0515,9067,721
Deferred revenue3,890     
Disposal group, including discontinued operation  2,2022,2022,2023,1114,157
Other liabilities2,683  693603637
Other undisclosed current liabilities  426684   
Total current liabilities:31,59630,95221,93822,93114,87422,432
Noncurrent Liabilities
Long-term debt and lease obligation:     2,894 
Liabilities, other than long-term debt33,1779,27435,03730,9397,6075,953
Deferred revenue20,038     
Deferred income tax liabilities   367367367549
Other liabilities4,4393,0741,5702,1723,1793,736
Operating lease, liability     2,894 
Business combination, contingent consideration, liability8,7006,20033,10028,4004,0611,668
Other undisclosed noncurrent liabilities     7,759 
Total noncurrent liabilities:33,1779,27435,03730,93918,2605,953
Total liabilities:64,77340,22656,97553,87033,13428,385
Equity
Equity, attributable to parent155,554157,179197,621197,34137,65069,912
Common stock1111  
Additional paid in capital1,058,317928,080880,832792,971542,286523,505
Accumulated other comprehensive income (loss)97(106)(897)(224)(94)(66)
Accumulated deficit(902,861)(770,796)(682,315)(595,407)(504,542)(453,527)
Total equity:155,554157,179197,621197,34137,65069,912
TOTAL LIABILITIES AND EQUITY:220,327197,405254,596251,21170,78498,297

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues18,72031,24929,7526,7616,4824,227
Cost of revenue(2,792)(3,423)(4,023)(4,713)(5,133)(4,055)
Gross profit:15,92827,82625,7292,0481,349172
Operating expenses(55,789)(137,425)(102,946)(67,432)(52,261)(111,230)
Other undisclosed operating income (loss)(102,071)12,242(12,637)(24,339)  
Operating loss:(141,932)(97,357)(89,854)(89,723)(50,912)(111,058)
Nonoperating income (expense)9,8678,5092,946(1,142)(424)(2,484)
Investment income, nonoperating9,867     
Other nonoperating income (expense)  8,5092,946(1,142)(424)(2,484)
Interest and debt expense    (752)(5)(87)
Other undisclosed income from continuing operations before equity method investments, income taxes     144 
Loss from continuing operations before equity method investments, income taxes:(132,065)(88,848)(86,908)(91,617)(51,197)(113,629)
Other undisclosed income (loss) from continuing operations before income taxes    752(139)(47,725)
Loss from continuing operations before income taxes:(132,065)(88,848)(86,908)(90,865)(51,336)(161,354)
Income tax benefit  367  182 
Loss from continuing operations:(132,065)(88,481)(86,908)(90,865)(51,154)(161,354)
Loss before gain (loss) on sale of properties:(90,865)(51,015)(161,354)
Income from discontinued operations     139 
Net loss available to common stockholders, diluted:(132,065)(88,481)(86,908)(90,865)(51,015)(161,354)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(132,065)(88,481)(86,908)(90,865)(51,015)(161,354)
Other comprehensive income (loss)203791(673)(130)(28)3
Comprehensive loss, net of tax, attributable to parent:(131,862)(87,690)(87,581)(90,995)(51,043)(161,351)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: